Hepatitis Test Solution Diagnosis Market Size To Expand at a Notable CAGR Of 3.86% During 2022 - 2030

Pune, India, January 2023 /MRFR Press Release/- Market Research Future published a half-cooked research report on the global hepatitis test solution/diagnosis market.

Market Highlights

The global hepatitis test solution/diagnosis market is expected to grow at an approximate CAGR of 3.86% during forecast period, 2022–2030 and is anticipated that the market held a value of USD 3233.89 Million by 2030.

Hepatitis is a liver infection caused by the hepatitis virus and results to cause liver inflammation, or sometimes liver damage. There is different type of hepatitis infection such as hepatitis A, hepatitis B, and hepatitis C which cause this infection. This pathological infection spreads through contaminated blood, infected medical devices and lasts for several years.

The patient suffering from hepatitis infection faces many symptoms such as poor appetite, weakness, weight loss, itching on skin, jaundice, dark-coloured urine, swelling on legs, drowsiness and many more. The key factors responsible to drive the market are rising awareness regarding the disease, growing adoption of innovative technologies, and increasing health care expenditure. According to the World Health Organization (WHO) 2018 fact sheet, it was estimated that 71 million population across the globe have chronic hepatitis C and it was also mentioned that approximately 399,000 number of people die each year from hepatitis infection. Such a large population affected by hepatitis infection boosts the market growth.

However, the factors such as side effects associated with the medications and treatment are expected to hinder the market growth.

Segmentation

The global hepatitis test solution/diagnosis market is segmented on the basis of disease type, technology, end user and region.

On the basis of disease type, the market is segmented into Hepatitis A, Hepatitis B, Hepatitis C and others.

The global hepatitis test solution/diagnosis market by technology is segmented into enzyme-linked immunosorbent assay (ELISA), rapid diagnostic tests (RDT), polymerase chain reaction (PCR), isothermal nucleic acid amplification technology (INAAT) and others.

On the basis of end-user, the market is categorized into hospital & diagnostic laboratories, blood banks and other.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Hepatitis Test Solution Diagnosis Market Research Report

Regional Analysis

The Americas dominates the global market for hepatitis test solution/diagnosis owing to the increasing awareness about hepatitis infection and various symptoms associated to it, rising geriatric population, and presence of major market players within the region. Additionally, the rising economy and high expenditure on healthcare sector within the region fuels the market growth during the forecast period. In 2017, it was estimated that Europe stood second in the global hepatitis test solution/diagnosis market due to increasing prevalence of hepatitis infection, kidney problem and other infectious diseases within the region.  Asia Pacific was the fastest growing region for the global hepatitis test solution/diagnosis market in 2017. Factors such as increasing awareness about the treatment methods, adoption of new technology, rapidly developing healthcare within the region drives the market growth within the region. On the other hand, the Middle East and Africa holds a least share in the global hepatitis test solution/diagnosis market. The presence of poor economies and low per capita income, especially within the African region make the market to lag within the region. A majority of the market share within this region is estimated to be held by the Middle East.

Key Players

Some of the key players in the global hepatitis test solution/diagnosis market are Abbott Laboratories Inc. (US), Biomérieux Sa (France), Bio-Rad Laboratories (US), Danaher Corporation (US), Diasorin (Italy), Fujirebio, Inc. (Japan), Grifols (USA), MedMira, Inc. (US), Qiagen (UK), Roche Diagnostics (UK), Siemens Healthineers (UK) and Others.